Chiasma Inc (NASDAQ:CHMA) has earned a consensus broker rating score of 5.00 (Strong Sell) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong sell recommendation.

Zacks has also given Chiasma an industry rank of 152 out of 265 based on the ratings given to related companies.

Chiasma (NASDAQ CHMA) traded down $0.06 during trading hours on Tuesday, reaching $1.48. The company’s stock had a trading volume of 187,400 shares, compared to its average volume of 111,189. Chiasma has a 1 year low of $1.25 and a 1 year high of $2.95. The firm has a market capitalization of $36.57 and a price-to-earnings ratio of -1.26.

Chiasma (NASDAQ:CHMA) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($0.28) earnings per share for the quarter.

An institutional investor recently bought a new position in Chiasma stock. Dimensional Fund Advisors LP purchased a new position in shares of Chiasma Inc (NASDAQ:CHMA) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 53,481 shares of the biotechnology company’s stock, valued at approximately $136,000. Dimensional Fund Advisors LP owned 0.22% of Chiasma at the end of the most recent reporting period. Hedge funds and other institutional investors own 54.56% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at

Chiasma Company Profile

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Get a free copy of the Zacks research report on Chiasma (CHMA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with's FREE daily email newsletter.